Mario Baroni

Istituti Clinici di Perfezionamento

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Giovanni Borsellino

Accademia Italiana Medicina Osteopatica

R Mondina

Accademia Italiana Medicina Osteopatica

F Polvani

University of Milan

Alfredo Pirondini

University of Milan

Silvano Poma

University of Milan

Salvatore Poma

Ospedale Vincenzo Cervello

Secchi Gc

Società Italiana di Medicina Generale

Augusta Sonato

Istituti Clinici di Perfezionamento

L Mondina

G. Robustelli della Cuna

Fondazione Salvatore Maugeri

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

University of Milan

Istituti Clinici di Perfezionamento

Agostino Gemelli University Polyclinic

Università Cattolica del Sacro Cuore

Istituto di Sessuologia Clinica

Policlinico S.Orsola-Malpighi

University of Bologna

Ospedale Maggiore

Sapienza University of Rome

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Plasma Steroid Transport in Subjects with Tumors of Hormonal Target Organs: A Review

Tumori Journal (1992)

Giovanni Borsellino Arturo Buonaguidi Mario Baroni Gaetano Elli Augusta Sonato

Tumors derived from a hormonal target organ are assumed to be stimulated by the same hormone that stimulates the normal target tissue. In spite of attempts to acquire direct indications of a correlation between hormones and cancer, none have been definitive because studies of total and free hormone levels have given contradictory results. For this reason, attention has shifted to the study of plasma binding and transport of hormones, that is, of the proteins responsible for modulation of the hormone effect and thus of hormone bioavailability. The data reviewed indicate that in-depth study of the transport and binding system of sex steroids would give new information about the endocrine characteristics of cancer patients.

Steroid hormone

10.1177/030089169207800302

Cite

Citations (1)

Breast carcinoma and skeletal formation

European Journal of Cancer (1992)

R Mondina Giovanni Borsellino Silvano Poma Mario Baroni Brunella Di Nubila

Breast carcinoma

10.1016/0959-8049(92)90458-e

Cite

Citations (14)

Development of laboratory hormone tests and their application in the monitoring of cancer patients.

PubMed (1986)

R Mondina Alfredo Pirondini Mario Baroni Giovanni Borsellino L Mondina

In the endocrinologic study of dysplastic and neoplastic pathologies of hormone-dependent organs we propose the determination not only of the plasma levels of the "total" hormone but also those of the free hormone as well as the plasma/hormone binding capacity and the kinetics of the plasma/steroid interaction.

Steroid hormone

Hormone Therapy

Source

Cite

Citations (0)

Breast carcinoma and plasma 17-β-estradiol binding

Cancer (1989)

R Mondina Giovanni Borsellino Alfredo Pirondini F Polvani Mario Baroni

The data relating to plasma steroid binding and transport (usually measured with dehydrotestosterone) are controversial. The plasma E2 binding of 79 breast carcinoma patients, 19 premenopausal and 60 postmenopausal, were compared to 46 controls, 21 premenopausal and 25 postmenopausal. In this study the authors removed the endogenous steroids with charcoal, incubated the plasma with 17-beta-E2 in non-saturation conditions, and used ammonium sulfate to precipitate the complex. The authors chose 17-beta-E2 as ligand because the plasma steroid binding system has not been shown to be homogeneous and because this binding function may vary independently for the different steroids. In these patients, the E2 binding was significantly (P less than 0.01) increased (85 +/- 11 pg/ml and 73 +/- 13 pg/ml in premenopausal and postmenopausal) compared to the normal controls (59 +/- 7 pg/ml and 58 +/- 5 pg/ml in premenopausal and postmenopausal women. It is still unclear whether this is a primary increase of the binding capacity or a reaction of the host for sequestering excess circulating E2. However, the small percentage of false-positives and false-negatives suggests that E2 binding could be used as a tumor marker in breast carcinoma.

Breast carcinoma

Medroxyprogesterone

10.1002/1097-0142(19890115)63:2<305::aid-cncr2820630217>3.0.co;2-1

Cite

Citations (5)

Current status of hormone receptor measurements in cancer patients.

PubMed (1986)

Alfredo Pirondini Mario Baroni Giovanni Borsellino Pietro Marchesi L Mondina

Despite increasingly sophisticated techniques, improvements in the correlation between laboratory findings and tumor response to endocrine therapy have not been obtained by hormone receptor studies. A possible explanation is that present knowledge of the mechanisms of the endocrine stimulus is incomplete. Some aspects of the present model, (elevated conjugated steroid levels, multiplicity of the plasma proteins capable of binding hormones, pulsatility of the plasma protein bond and of the receptor system for steroids), are still unclear and thus are not used in diagnosis. By evaluating these factors it will probably be possible to correlate better laboratory data with clinical findings.

Source

Cite

Citations (0)

Steroid receptor enhancement by natural interferon-β in advanced breast cancer

European Journal of Cancer (1993)

Gigliola Sica Fortunata Iacopino Gina Lama D. Amadori Mario Baroni

Steroid hormone

BETA (programming language)

Progesterone receptor

Oestrogen receptor

10.1016/0959-8049(93)90378-s

Cite

Citations (17)

Clinical trial of combined hormone therapy (MAP + TAM) for metastatic breast cancer.

PubMed (1984)

F Pannuti Andrea Martoni E Piana Luciana Tomasi Antonio Grieco

High dose MAP (medroxyprogesterone acetate) and TAM (tamoxifen) were administered orally to 31 postmenopausal patients with advanced breast cancer. CR (complete remission) was achieved in 1 (3%) and PR (partial remission) in 11 (32%) patients for a median duration of 12 months. The treatment was well tolerated and in no instance was interrupted because of toxicity. This study does not support the hypothesis that the combination of MAP and TAM gives better results than the single agents.

Hormone Therapy

Source

Cite

Citations (1)